Login to Your Account



Sprung from the Ashes

Geron ESC Assets Regenerate at Asterias Biotherapeutics

By Marie Powers
Staff Writer

Thursday, April 4, 2013
A 300-page S-1 filing with the SEC on Wednesday revealed that Geron Corp.'s human embryonic stem cell (ESC) assets, left dangling when the company abandoned the field in late 2011, will be reborn at Asterias Biotherapeutics Inc., a newly formed subsidiary of regenerative medicine specialist BioTime Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription